Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

This study involved people with ALL whose cancer had returned after, or stopped responding to, previous treatment. These people received either inotuzumab ozogamicin (InO for short) or standard chemotherapy. Researchers divided people into groups, based on the level of lymphoblast cells they had in their bone marrow (called disease burden): low, medium, or high disease burden. In this study, compared with people who received standard chemotherapy, people who received InO were more likely to have no signs of their cancer (called remission), live to the end of the study, and/or reach the end of the study without their cancer getting worse. The researchers saw these results across all disease burden groups. For people who received InO, those with high disease burden were equally as likely as those with low disease burden to achieve remission, and/or experience medical problems. For people who received standard chemotherapy, those with high disease burden were less likely than those with low disease burden to achieve remission. Further information in a plain language format is available in Supplementary Information (SI) Fig. S1.

Source: Blood Cancer Journal - August 6, 2020 Category: Hematology Authors: Daniel J. DeAngelo Anjali S. Advani David I. Marks Matthias Stelljes Michaela Liedtke Wendy Stock Nicola G ökbuget Elias Jabbour Akil Merchant Tao Wang Erik Vandendries Alexander Neuhof Hagop Kantarjian Susan O ’Brien Source Type: research